Available Online at www.ijcsmc.com

International Journal of Computer Science and Mobile Computing

A Monthly Journal of Computer Science and Information Technology

ISSN 2320–088X

IJCSMC, Vol. 4, Issue. 6, June 2015, pg.121 – 125

RESEARCH ARTICLE

Novel Biomarkers for Diagnosis of Rheumatic Arthritis

Priyanka Premnath[1], Dr. K.B.Ramesh[2], Dr. Vidya Niranjan[3], Dr. B.P.Mallikarjunaswamy[4], Dr. E.T.Puttaiah[5]

Dept. of Biomedical Signal Processing and Instrumentation[1], M.Tech[1]

Dept. of Electronics and Instrumentation Engineering[2], Associate Professor & Head[2]

Dept. of BioTechnology[3], Professor & Associate Dean[3]

Department of Computer Science and Engineering[4], Professor[4]

Department of Environmental Science[5], Professor[5]

priyankapremnath@gmail.com 1, k_b_ramesh@hotmail.com 2, niranjan.vidya@gmail.com 3

ABSTRACT- Rheumatic joint pain (RA) is an unending systemic immune system illness encapsulating aggravation and perpetual harm of the joints. Early treatment in RA is vital as it can anticipate infection movement and irreversible harm of the joints. Powerful finding and treatment of the malady is a test because of its heterogeneity. The flow indicative tests are not adequately exact to describe the infection at ahead of schedule stages. Accordingly, RA is regularly analyzed just once harm to the joints has as of now started, a period at which the time for ideal treatment may have been missed. Consequently, there is an in number interest for novel serological biomarkers to enhance the early analysis and compelling stratification of this dynamic infection, so that the patient is given focused on and opportune treatment. Biomarkers can redo the administration of RA by empowering the early finding, appraisal and expectation of malady seriousness, determination of treatment, and checking of reaction to treatment. In this audit, we talk about the different biomarkers of RA.

KEYWORDS: Proteins, genes, Rheumatic Arthritis, antibodies, cytokines, biomarkers

I. INTRODUCTION

Rheumatic joint inflammation (RA) is a typical, exemplary immune system infection that outcomes in an unending, systemic incendiary issue and happens in around 1% of the grown-up populace. RA mainly influences synovial tissues as well as different tissues and instinctive organs, for example, heart, pericardium, and lungs. Amid the early stage, RA influences joints of the hand and foot and in later stages, different joints and once in a while the spine. Long haul results connected with RA are erosive joint obliteration, disfigurement and utilitarian disability. [3] Current clinical determination of RA are taking into account side effects, physical exams, radiographs and the vicinity of autoantibodies and incendiary markers. The serum levels are weighed in the labs to distinguish levels of rheumatoid component (RF) and against citrullinated protein antibodies (ACPAs), particularly hostile to CCP (cyclic citrullinated peptide). Be that as it may, these tests show inspiration in just a small amount of the RA populace (15% for RF, 60-70% for hostile to CCP), and are not present in various patients with the condition. Essentially it is found that individuals having the RF component positive don't create RA. Henceforth managing such a heterogeneous sickness makes it

troublesome for the early recognition with just a solitary biomarker. At first the patients with joint torments and demonstrating joint inflammation side effects are treated with undifferentiated joint inflammation treatment until they demonstrate six weeks of persistent joint agony and meet the predefined RA condition given by the US Nourishment and Medication Organization (FDA) [7]. RA patients are then controlled treatments on an experimentation premise, the drug measurement are differed from patient to patient contingent upon the seriousness, additionally presentation of extra treatments, and change of treatment prompted if the patient does not react acceptably or encounters unfriendly symptoms. Subsequently a novel biomarker is obliged to foresee the early onset of the malady, characterize the seriousness or phases of the infection furthermore assess the patients reaction to the treatment. The heterogeneity of the sickness and a quiet's particular hereditary qualities make the intercession of focused on treatment an unquestionable requirement. Focused on treatment implies particular treatment to a particular infection to a particular person. For the focused on treatment the significant parts are, as they describe the natural movement of the individual making it simple for the forecast and additionally distinguishing the reaction to the treatment. As these biomarkers are exceptional to the infection the vicinity of these markers in an individual can record to the presence of a specific obsessive condition.

Biomarkers can be characterized into different sorts, for example, clinical, histological, or imaging parameters and atomic biomarkers. Sub-atomic biomarkers can be further characterized into genomic, proteomic, and lipidomic biomarkers. They can reflect changes that happen right on time in the illness movement or in the reaction to treatment and are along these lines considered a standout amongst the most profitable sort of biomarker — both for location of infection instruments and restorative targets and for clinical choice making. In select cases, a solitary biomarker will suffice. Yet, for RA a solitary biomarker is inadequate to recognize the infection to the shifting hereditary make-up of the people. The headway in biomarker field the previous decade has cleared a route for ahead of schedule forecast of the sickness. Joining the biomarkers with the exceedingly progressed and promising genomic and proteomics procedures, they can be utilized as a marker of the neurotic.

II. BIOMARKERS USED FOR RA DETECTION

The below tables 1 gives a brief details about the different biomarker genes of RA along with the chromosome location they are located in. Also gene expression they undergo.

Sr. No	Responsible Gene	Gene Expression	Chromosome located
1	CD19	Over Expressed	16
2	CRP	Increase.	1
3	CXCL13	Over Expressed	4
4	CYR61	Highly expressed	1
5	FCN3	SNP	1
6	HLA-DRB1	Highly expressed	6
7	HLA-DRB4	Highly expressed	6
8	MMP9	Highly expressed	20
9	PADI4	SNP	1
10	STAT3	Highly expressed	17
11	VIM		10
12	HOXD10,	Highly expressed	2
13	MAB21L2	Highly expressed	4
14	ICAM1	Not expressed	19
15	RGS16	Not expressed	1
16	GATA6	Not expressed	18
17	Laverin	Highly expressed	
18	HOXD11	Highly expressed	2
19	HOXD13	Highly expressed	2
20	CCL8	Highly expressed	17
21	LIM homeobox 2	Highly expressed	9

Table 1: Details of RA biomarkers

III. METHODOLOGY

The functional block diagram 1 below depicts the steps involved in the implementation of the project.



Fig 1: Block diagram of the system

The Biomarker succession is in charge of RA is downloaded from the standard database NCBI of both typical and RA groupings. The procedure is broken into four primary components. The first segment in the process is to outline the left and right groundworks for the distinguished biomarkers. Likewise the underlining genomics and polymorphism of the biomarkers are studies utilizing which the sickness is arranged into Stage 1, Stage 2 and Stage 3. The second step includes in the handling of biomarker successions and the information DNA record of the patient. The third stage, the investigation device, is the most essential part all the while. In this stride, the read DNA document is checked for the vicinity of all biomarkers planned. Contingent on the vicinity of biomarkers the module presentations come about as to if RA is available in the patient or not. At last, the last step is the grouping malady into different stages relying on which all biomarkers were available in the DNA data record.

IV. CONCLUSION

The heterogeneity of RA makes it unrealistic to have a solitary, exceptional biomarker to analyze or foresee the advancement of malady. A biomarkers as being what is indicated ought to be particular to RA, ought to anticipate the movement of ailment, and spread an extensive variety of RA patients. Just a blend of elements seems to satisfy these necessities. A portion of the potential biomarker mixes include: recognition in the change in immunological parameters like cell energy alongside the arrangement of autoantibodies, particular cytokine changes and different markers of malady defenselessness. Multicenter studies investigating these components ought to help enhance their quality as biomarkers of ahead of schedule RA.

REFERENCES

[1] S.Chandrashekara, "Current studies of biomarkers for the early diagnosis of rheumatoid arthritis", DovePress Journal , Current Biomarker Findings, Sept 2014:4 107–119

[2] Agata Burska, Marjorie Boissinot, and Frederique Ponchel, "Cytokines as Biomarkers in Rheumatoid Arthritis" Mediators of Inflammation Volume 2014 (2014), Article ID 545493

[3] Leendert A. Trouw , Michael Mahler, "Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis" , 2012 Elsevier B.V. Autoimmunity Reviews 12 (2012) 318–322

[4] Cathy M McGeough and Anthony J Bjourson ,"Diagnostic, Prognostic and Theranostic Genetic Biomarkers for Rheumatoid Arthritis", Clinical & Cellular Immunology (2012) , J Clin Cell Immunol S6:002. doi:10.4172/2155-9899.S6-002

[5] Tamsin M. Lindstrom and William H. Robinson, "Biomarkers for rheumatoid arthritis: Making it personal", Scand J Clin Lab Invest Suppl. Jul 2014; 242: 79–84. doi: 10.3109/00365513.2010.493406

[6] Sajid A.Marhon, Stefan C.Kremer "Gene prediction based on DNA spectral analysis: A literature survey," Journal of computational biology, vol. 18, no. 4, 2011.

[7] Peter Taylor, Juliane Gartemann, Jeanie Hsieh, and James Creeden ,"A Systematic Review of Serum Biomarkers Anti-Cyclic Citrullinated Peptide and Rheumatoid Factor as Tests for Rheumatoid Arthritis", Autoimmune Diseases Volume 2011 (2011), Article ID 815038

[8] Morten A Karsdal, Thasia Woodworth, Kim Henriksen, Walter P Maksymowych, Harry Genant, Philippe Vergnaud,Claus Christiansen, Tanja Schubert, Per Qvist, Georg Schett, Adam Platt and Anne-Christine Bay-Jensen "Biochemical markers of ongoing joint damage in rheumatoid arthritis - current and future applications, limitations and opportunities",, BioMed Central Ltd Arthritis Research & Therapy 2011, 13:215

[9] Anna Gramling, Anna Gramling "Initial Management of Rheumatoid Arthritis", Elsevier Inc, Rheum Dis Clin N Am 38 (2012) 311–325

[10] Eric Ruderman, Siddharth Tambar," Rheumatoid arthritis",© 2012 American College of Rheumatology

[11] BCGuidelines.ca: "Rheumatoid Arthritis: Diagnosis, Management and Monitoring"(2012)

[12] Rohini Handa ,"New Classification Criteria for Rheumatoid Arthritis and Ankylosing Spondylitis", Medicine Update 2012 , Vol. 22

[13] Christina H. Opava, Ralph Nisell, "Rheumatoid arthritis" physical activity in the prevention and treatment of disease

[14] Min Wu, Fan-Fang Zeng, Run Wang, Wai-Key Seto, Pearl Pai, Patrick Chu and Kai-Hang Yiu2 "Atherosclerosis in Patients with Rheumatoid Arthritis", Rheumatol Curr Res 2013, S5, ISSN: 2161-1149 Rheumatology

[15] GARY S. FIRESTEIN "Etiology and Pathogenesis of Rheumatoid Arthritis", FIRESTEIN

[16] Katia Chanin, Federico Vallejo-Manzur, George L. Sternbach, Robert Fromm, Joseph Varon, "Pulmonary Manifestations of Rheumatoid Arthritis C h a n i n e t a l Hospital Physician July 2001: p p . 2 3 – 2 8

[17] Pnina Fishman and Sara Bar-Yehuda "Rheumatoid Arthritis: History, Molecular Mechanisms and Therapeutic Applications", DOI 10.1007/978-90-481-3144-0_15, c Springer Science+Business Media B.V. 2010

[18] K.B Ramesh, S.J Shibani Prasad, Dr. B.P. Mallikarjunaswamy,Dr. E.T.Puttaiah, "Prediction and Detection of Rheumatoid Arthritis SNPs Using Neural Networks", IOSR Journal of Pharmacy and Biological Sciences , e-ISSN: 2278-3008, p-ISSN:2319-7676. Volume 9, Issue 1 Ver. V (Feb. 2014), PP 06-09

[19] Vanja Pauni´c, Michael Steinbach, Vipin Kumar ,"Prediction of HLA Genes from SNP Data and HLA Haplotype Frequencies" 978-0-7695-4925-5© 2012 IEEE

[20] J.A. Mendonça, M.A. Yazbek, I.M.M. Laurindo and M.B. Bertolo," Wrist ultrasound analysis of patients with early rheumatoid arthritis", Braz J Med Biol Res, January 2011, Volume 44(1) 11-15

[21] James Connolly, Joan Condell, Kevin Curran ,"A new method to determine joint range of movement and stiffness in Rheumatoid Arthritic Patients", 978-1-4577-1787-1©2012 IEEE

[22] Anand A. Joshi , Richard M. Leahy, Ramsey D. Badawi, Abhijit J. Chaudhari "MORPHOMETRY FOR EARLY MONITORING OF TREATMENT RESPONSE IN

[23] RHEUMATOID ARTHRITIS", 978-1-4673-6455-3/13 ©2013 IEEE

[24] Yinghe Huo, Koen L. Vincken , Max A. Viergever , Floris P. Lafeber "AUTOMATIC JOINT DETECTION IN RHEUMATOID ARTHRITIS HAND RADIOGRAPHS", 978-1-4673-6455-3/13/ ©2013 IEEE

[25] Andreas Koch, Stephanie Finzel, Andreas Kobler, Georg Schett, Reinhard Lerch and Helmut Ermert "In-vivo results for rheumatoid arthritis diagnosis with a 360_ pulse-echo imaging system" 978-1-4673-4562-0/12 ©2012 IEEE

[26] Georg Langs , Philipp Peloschek , Horst Bischof, Franz Kainberger "Automatic Quantification of Joint Space Narrowing and Erosions in Rheumatoid Arthritis", IEEE TRANSACTIONS ON MEDICAL IMAGING, VOL. 28, NO. 1, JANUARY 2009

[27] V. Goe¨b, P. Dieude´, R. Daveau, M. Thomas-L'Otellier, F. Jouen, F. Hau, P. Boumier, F. Tron,D. Gilbert, P. Fardellone, F. Corne´lis, X. Le Loe¨t and O. Vittecoq "Contribution of PTPN22 1858T, TNFRII 196R and HLA-shared epitope alleles with rheumatoid factor and anti-citrullinated protein antibodies to very early rheumatoid arthritis diagnosis" Rheumatology 2008;47:1208–1212

